OUTLOOK : Rates below double figures will be a triumph

No mock horror about the latest interest rate rise, please. The market expected it to happen, this month or next, and if the lid is kept on house prices as a result of higher mortgage rates there will be rejoicing in Threadneedle Street.

The Bank of England, foiled in its Scrooge-like hopes of a miserable Christmas for retailers, does not want to see the present buoyancy of manufacturing spreading to householders, boosting spending in a potentially inflationary way. Eddie George, the Governor of the Bank, said last month that a stitch in time saves nine. He meant that if the upward movement starts early the cycle is bound to peak at a lower rate than it would otherwise have done. What he and the rest of us have to guess - because the Go vernor and the Chancellor are as much in the dark about it as anybody - is how much lower and what would the peak have been in an unreconstructed world in which politicians continued to keep interest rates down until too late?

The average of past interest rate cycles is a movement of 6 percentage points from peak to trough, which would take rates to 11.25 per cent this time round. Clearly, much has changed in the aftermath of the 1990 recession. Inflation is far lower, while fiscal policy is tight compared with most past recoveries. And, of course, interest rate strategy has changed for the better.

But the consensus in the markets that the peak is no more than a percentage point above today's new level is based on an all-too-eager readiness to believe that changes in behaviour can be both complete and instantaneous.

There is still a very real possibility that rates will rise very near to 10 per cent. If the tax giveaway is as great as everyone expects in the next Budget, they might, by rights, have to go higher still. In reality, anything even fractionally below double figures will represent a triumphant break with the past.

Wellcome should forget search for white knight It is early days yet but Wellcome's search for a white knight looks an increasingly desperate affair. Even a 19 per cent upswing in pre-tax profits to £738m was insufficient to persuade the market that the company is worth any more than the £10.25 a share Glaxo is offering. As far as the stock market is concerned, this is already a done deal. The board's opposition is largely an irrelevance.

One after another potential rivals are ruling themselves out. There are still some left with the $15bn of firepower it would take to outbid Glaxo - Merck is one - but it is hard to see why they should take the plunge. Wellcome would clearly prefer a bidder that would allow the company a degree of continued independence. It would, however, be naive to think anyone would pay that amount of money just to allow Wellcome to play around in the back yard.

Any takeover is bound to involve rationalisation. By talking to rivals, even before Glaxo made its bid, Wellcome implicitly recognised the consolidation taking place in this industry. Wellcome was always going to get dismembered. The existence of a substantial shareholder, the Wellcome Trust, which wants to sell out, meant it could never take the active role in the process of change in the pharmaceuticals industry.

Glaxo's position is in a way unfortunate. It looks like the rapist. Certainly that is how Wellcome would like it to be seen. But the reality is that whoever ends up with Wellcome will go through exactly the same slash and burn process.

For Glaxo, however, this is not merely a cost-cutting exercise. It is a considered and bold approach to the two revolutions taking place in pharmaceuticals. One is the shift in market power from producer to purchaser, requiring dramatic changes in organisation and marketing. The other is in science and technology. Gone are the days when drugs were stumbled upon by accident and the mechanism by which they work discovered later. Today the mechanism comes first and the drug is designed against it. According to Glaxo, Wellcome by itself would be incapable of sustaining the sort of research facility that success in pharmaceuticals requires.

Wellcome owes it to its shareholders to explore all available opportunities. On the other hand, to give preference to an American bidder over Glaxo is unlikely to be in the company's, or Britain's, best interests. The sooner the search for that illusory white knight is exhausted and the serious discussion on how to go forward together begins, the better.

So-so evidence on money for old rope Is nothing sacred in the City any more? It seems not. Not so long ago the idea of some busybody government regulator daring to investigate the way that the City organises its activities would have been regarded with horror, bordering on outrage. Since Bi g Bang, and the Lloyd's nightmare, however, all that has gone by the board. Everything, including time-honoured custom and practice, is now fair game. The future of the rights issue, a central plank in the UK system of corporate finance, is again in the frame.

There is plenty of prima facie evidence that the system of paying comissions for underwriting share issues - though it has stood the test of time - is potentially anti-competitive, and imposes unnecessary costs on firms seeking to raise new equity capital.

Whether this would justify Sir Bryan Carsberg, director-general of the Office of Fair Trading, ordering a Monopolies and Mergers Commission investigation, as reports suggested yesterday, is another matter. He has been canvassing opinions from vested interests, including merchant banks, brokers and fund managers. On his files, if he needed supporting evidence, is a report from Paul Marsh, a distinguished professor at London Business School, which suggests institutions are earning excess profits from their underwriting activites.

Alas for those who like a good scare story, the chances that Sir Bryan will trigger an MMC enquiry look slim. Sir Bryan recognises a complex issue when he sees one. He also has, by regulator standards, an unusual amount of common sense. He knows that a reference is not necessarily the best way to get to grips with this particular thorny issue. A better outcome could be to publish a high-profile report, and - if overcharging is demonstrated - let market forces determine whether changes are needed.

Nobody would deny that underwriting costs are an important part of the wider, highly political, debate about the cost of capital in this country. Is the established method of raising capital by rights issues cost-effective and fair? The evidence is so-soat best.

International comparisons show that the rights issue method is not that expensive. The administrative costs of the American alternative, general market placements, are higher. But this does not alter the impression that the fees, and notably the underwriting charges, are excessive. Privately, big institutions that sub-underwrite these issues admit it is mostly money for old rope. But if fundamental change is desired, then the only way to achieve this would be to scrap pre-emption rights. The merest hintof this is sure to provoke ferocious opposition across a wide front.

Start your day with The Independent, sign up for daily news emails
ebooksAn unforgettable anthology of contemporary reportage
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Digital Optimisation Executive - Marketing

£30000 - £35000 per annum: Recruitment Genius: The UK's fastest growing, multi...

Recruitment Genius: Financial Reporting Manager

£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...

Recruitment Genius: Payments Operations Assistant

£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...

Recruitment Genius: Telephone Debt Negotiator

£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...

Day In a Page

Syria civil war: Meet the military commander who says his soldiers will not rest until every inch of their war torn country is free of Islamist 'terrorists'

‘We won’t stop until Syria is back to normal’

Near the front lines with Islamist-controlled towns where Assad’s troops were besieged just last month, Robert Fisk meets a commander confidently preparing his soldiers for battle
Fifa corruption: Strip Qatar of the World Cup? Not likely

Strip Qatar of the World Cup? Not likely

But if a real smoking gun is found, that might change things, says Tom Peck
Twenty two years later Jurassic Park series faces questions over accuracy of the fictional dinosaurs in it

Tyrannosaurus wrecked?

Twenty two years on, Jurassic Park faces questions over accuracy
The inside story of how Bill Clinton built a $2bn global foundation may undermine Hillary's chances

The inside story of how Bill Clinton built a $2bn global foundation...

... and how it may undermine Hillary's chances in 2016
Genes greatly influence when and how many babies a woman will have, study finds

Mother’s genes play key role in decision to start a family

Study's findings suggest that human fertility is still evolving
12 best olive oils

Extra-virgin, cold-press, early-harvest, ultra-premium: 12 best olive oils

Choosing an olive oil is a surprising minefield. Save yourself the hassle with our handy guide
Rafa Benitez Real Madrid unveiling: New manager full of emotion at Bernabeu homecoming

Benitez full of emotion at Bernabeu homecoming

There were tears in the former Liverpool manager’s eyes as he was unveiled as Real Madrid coach. But the Spaniard knows he must make tough decisions if he is to succeed
England can win the Ashes – and Elvis Presley will present the urn

England can win the Ashes – and Elvis will present the urn

In their last five Test, they have lost two and drawn two and defeated an India side last summer who thought that turning up was competing, says Stephen Brenkley
Sepp Blatter resignation: The beginning of Fifa's long road to reform?

Does Blatter's departure mean Fifa will automatically clean up its act?

Don't bet on it, says Tom Peck
Charles Kennedy: The baby of the House who grew into a Lib Dem giant

The baby of the House who grew into a Lib Dem giant

Charles Kennedy was consistently a man of the centre-left, dedicated to social justice, but was also a champion of liberty and an opponent of the nanny-state, says Baroness Williams
Syria civil war: The harrowing testament of a five-year-old victim of this endless conflict

The harrowing testament of a five-year-old victim of Syria's endless civil war

Sahar Qanbar lost her mother and brother as civilians and government soldiers fought side by side after being surrounded by brutal Islamist fighters. Robert Fisk visited her
The future of songwriting: How streaming is changing everything we know about making music

The future of songwriting

How streaming is changing everything we know about making music
William Shemin and Henry Johnson: Jewish and black soldiers receive World War I Medal of Honor amid claims of discrimination

Recognition at long last

Jewish and black soldiers who fought in WWI finally receive medals after claims of discrimination
Beating obesity: The new pacemaker which helps over-eaters

Beating obesity

The new pacemaker which helps over-eaters
9 best women's festival waterproofs

Ready for rain: 9 best women's festival waterproofs

These are the macs to keep your denim dry and your hair frizz-free(ish)